Although TRPV4 inhibition would be an interesting target for pain, deafness, incontinence, and osmoregulation, deficits were observed in TRPV4-knockout mice, which questions the clinical utility of TRPV4 antagonists [138,139,140]. This evidence concerns the gene TRPV4 and deafness.